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Abstract
Transcriptional activator-like effector nucleases (TALENs) have become a powerful tool for genome editing. Here we
present an efficient TALEN assembly approach in which TALENs are assembled by direct Golden Gate ligation into
Gateway® Entry vectors from a repeat variable di-residue (RVD) plasmid array. We constructed TALEN pairs
targeted to mouse Ddx3 subfamily genes, and demonstrated that our modified TALEN assembly approach efficiently
generates accurate TALEN moieties that effectively introduce mutations into target genes. We generated “user
friendly” TALEN Entry vectors containing TALEN expression cassettes with fluorescent reporter genes that can be
efficiently transferred via Gateway (LR) recombination into different delivery systems. We demonstrated that the
TALEN Entry vectors can be easily transferred to an adenoviral delivery system to expand application to cells that
are difficult to transfect. Since TALENs work in pairs, we also generated a TALEN Entry vector set that combines a
TALEN pair into one PiggyBac transposon-based destination vector. The approach described here can also be
modified for construction of TALE transcriptional activators, repressors or other functional domains.
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Introduction
Generation of genetically modified animal models, as well as
creation of mutations and correction of mutants in human cells,
have provided many important tools for investigating gene
function, genetic disease and drug development [1,2].
Modification of a specific gene/locus in mammalian cells has
been a time-consuming task, because it usually involves
homologous recombination, which happens at a low rate in
nature. However, the efficiency of genetic modification at the
target locus could be increased hundreds to thousands fold by
creation of a site-specific double-stand break (DSB) through
designing “customized” nucleases. Repair of a DSB can occur
by two potential pathways: non-homologous end-joining
(NHEJ) or homologous recombination (HR). Currently, there
are at least four different customized nuclease systems have
been developed (see below), and assembly of customized
nucleases systems is becoming more efficient [3–6].
Zinc-finger nucleases (ZFNs), which emerged a decade ago
[7], are artificial nucleases consisting of engineered sequence-
specific Cys2His2 zinc-finger DNA-binding domains (3 or more
zinc fingers) and a FokI endnucleases cleavage domain.
Although tremendous progress has been made to improve the
specificity and affinity of zinc finger domains that recognize
desired DNA sequences, the target site overlap and crosstalk
between individual fingers make it complicated to design and
select sequence-specific ZFNs [7], which has impeded
researcher access. Homing endonucleases, such as
LAGLIDADG family members, have also been engineered for
genome editing. Homing endonucleases directly involve DNA
sequence recognition and cutting process as well. The
drawback is that the production of homing endonucleases
targeted to specific sequences appeared to be more
complicated [8–11].
TALENs, like ZFNs, are also composed of two parts, DNA
binding domain and a FokI endnuclease cleavage domain. The
DNA binding domain is similar to TALE proteins isolated from
plant pathogenic bacteria in Xanthomonas genus, whose DNA
targeting specificity is determined by tandem 33-35 amino acid
repeats, followed by a truncated repeat. The tandem repeats
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with polymorphisms locate at positions 12 and 13, termed the
repeat variable di-residues (RVDs), recognize one of four
nucleotides in the target sequence [12,13]. Because TALEs
show no context dependency [14], this relationship of RVDs to
bases permits engineering of custome TALE RVDs arrays that
recognize any defined sequences [15–20] . Initially, some
guidelines for TALEN site selection had been suggested [18].
However, subsequent studies suggest that the rules may exist
in natural TALE, but are not necessary for designing artificial
TALENs, which gives TALEN assembly more flexibility
[16,17,19]. A large-scale in vivo analysis reveals that TALENs
are significantly more mutagenic than ZFNs [21]. So far,
TALENs have been used for genome editing in various
organisms, such as different plants [18,22,23], yeast [18,24],
fruitflies [25], fish [26–29], hamster [30], mouse [31–33], rat
[34] , cattle [35], and human cells [17–20,29,36–40] . TALE
transcriptional activators have also been developed to up-
regulate gene expression or down regulation by transcriptional
repression by replacing the FokI endnuclease cleavage domain
with the transcriptional activator VP16 [15,41,42] or
transcriptional repressor mSin interaction domain (SID) [43].
The CRISPR/Cas system is a defense system evolved in
bacteria and archaea that use short RNA to directly degrade
foreign nucleic acids. Recently, the S. pyogenes type II
CRISP/Cas 9 based system has been developed for genome
editing in mammalian cells. In this system, the mature crRNA
base-paired to trans-activating trans-crRNA that directs the
Cas protein to introduce DSBs in target DNA [44–47].
Designing CRISP/Cas 9 system to target a specific sequence
is simpler than the TALEN system. However, a relative large-
scale analysis demonstrated that it shows significant off-target
activity which may limit its application, especially for cell
therapy [48].
Several different scaffolds and protocols for assembly of
TALE RVDs have been reported [15–17,19,20,32]. In this
study, based on the TALEN scaffold of Zhang’s group [15], we
constructed a set of RVDs and TALEN entry vectors which
allow us to efficiently and accurately assemble customized
TALENs. Furthermore, through Gateway® LR recombination,
the assembled TALEN can be easily transferred into an
adenoviral vector system, which facilitates delivery of TALEN
into cells. We also demonstrated that a pair of TALENs can be
merged into a single plasmid, which is convenient for
transfection or injection. Using these modified tools, we
generated three pairs of TALENs which target the Ddx3
subfamily of DEAD-box RNA helicase genes in mouse, Ddx3x,
Ddx3y and D1Pas1(Pl10) and validated their function by
Surveyor mutation analysis and sequencing of target genes.
The TALEN assembly system described here has the flexibility
for application to other TALE related vectors.
Materials and Methods
Plasmid construction
A plasmid array encoding TAL repeat variable di-
residues (RVDs).  By using the plasmids encoding four RVDs
(NI, NN, HD or NG for recognition of A, G, C and T nucleotides,
respectively), a total of forty TAL RVDs were amplified by using
the primers as reported previously [15]. However, twelve RVDs
of the first position of hexamers were re-amplified through
primer Ex-F: 5’-GACAGATCT CGTCTC
ATGGCCAACCTTAAACCGGCCAACATAC-3’ and reverse
primer In-R1: 5’-
TCTTATCGGTGCTTCGTTCTCGTCTCCCGTAAGTCCGTGC
GCTTGGACAC-3’. Thus, six RVDs can be ligated directly into
the intermediate plasmid pTemp-S (see below), rather than the
original RVDs, which were ligated to form circular hexamers
[15]. All of these RVDs fragments were then cloned into pGEM-
T vector (Promega, A3600 ) by TA cloning and sequenced. The
resulting RVD plasmid array will be made available for other
researchers upon request.
pTemp-S
A fragment containing LacZ-ɑ was amplified through a
forward primer: 5’-gcat
cttaagaattcgtctccgaacctaccaagtggtggctatcgagac-3’ and a
reverse primer: 5’-
cgactctagacgtctccgttcagtaccggtggaaagcgggcagtc-3’ using
pFUS_B4 (Addgene #31021) as a template. This fragment was
inserted into pFUS_B4 between AflII and XbaI sites to generate
an intermediate plasmid, named pTemp-S, to facilitate
assembly in subsequent steps.
TALEN expression Entry vectors
To generate TALEN Entry plasmids with reporters, we first
created plasmid pT2A-EGFP-N3, pEGFP-T2A-C1, pT2A-
mCherry-N3 and pmCherry-T2A-C1 by annealing oligos 5’-
AATTCTGGCAGTGGAGAGGGCAGAGGAAGTCTGCTAACA
T GCGGTGACGTCGAGGAGAATCCTGGCCCAG-3’ and 5’-
TCGACTGGGCCAGGATTCTCC
TCGACGTCACCGCATGTTAGCA
GACTTCCTCTGCCCTCTCCACTGCCAG-3’,which contain the
T2A sequence and inserted them into the EcoR1/SalI sites of
pEGFP-N3 (Clontech, #6080-1) , pEGFP-C1 (Clontech,
#6084-1), pmCherry-C1 (Clontech, #632524 ) and pmCherry-
N3. We constructed the pmCherry-N3, which is not
commercially available, by replacement of the EGFP cDNA
between the BamHI and NotI sites in pEGFP-N3 with mCherry
cDNA. The primers for mCherry cDNA amplification are
forward, 5’-
AATGGATCCATCGCCACCATGGTGAGCAAGGGCGAGGAG
GAT-3’, and reverse, 5’-
GAGTGCGGCCGCTACTTGTACAGCTCGTCCATGCCGCCG
GT-3’.
For the standard TALEN Entry plasmids, T2A-EGFP and
T2A-mCherry fragments were amplified by PCR with a
common forward primer 5’-
CGATGAATTCGGCAGTGGAGAGGGCAGA GGAAGTC-3’
and reverse primer 5’-CTCGCTAGCCTA
TGGCGCGCCTTACTTGTACAGCTCGTCCA TGCCGAG-3’
for EGFP or reverse primer 5’-
CTCGCTAGCCTATGGCGCGCCCTACTTGTACA
GCTCGTCCATGCCGCCGGT-3’ for mCherry. The amplified
products were inserted into the EcoRI/XbaI sites of pEF-ENTR
A (Addgene #17427) to create pENTR-EF-T2A-EGFP or
pENTR-EF-T2A-mCherry. Using the pTALEN_V2 TALEN
Assembly of Customized TALENs
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plasmids as templates [15], the N-terminal sequences were
amplified using forward primer 5’-
GATAGATCTACTAGTATGGACTATAAGGACCACGAC-3’ and
reverse primer 5’-GGTACATTGAGCAACTGACTG-3’, then
digested with SpeI/NotI. The C-terminal sequences of the
pTALEN_V2 TALEN plasmids were amplified using forward
primer 5’- CCAGTTGCTGAAGATCGCGAAGC-3’ and reverse
primer 5’- TTAGAATTCTGGCGCGCCTG
AGCGGAAATTGATCTCGCCATTG-3’, then digested with NotI/
EcoRI. These N-teminal and C-terminal fragments were ligated
into the SpeI/EcoRI sites of pENTR-EF-T2A-EGFP or pENTR-
EF-T2A-mCherry (Table 1).
To generate the TALEN ”2 in 1” Entry plasmids, we first
removed the EF1α promoter from pEF-ENTR A by HindIII
digestion and re-ligation to generate pENTR-Promoterless.
This plasmid was amplified by PCR using forward primer 5’-
TCCACCATGGGAACCGACATTG-3’ and  reverse primer 5’-
GTGTCGACAACTTTTGTATACAAAGTTGGC-3’ and ligated to
create pattL5-attL2 (pL5L2). For pattL1-attR5 (pL1R5), the
oligos 5’-CAACTTTGTATACAAAAGTTG
AACGAGAAACGTAAAATGATATAAATATCAATATATTAAATT
AGATTTTGCATAAAAAAC-3’ and 5’-
CATAGTGACTGGATATGTTGTGTTTTACAGTATTATGTAGT
CTGTTTTTTATGCAAA ATCT-3’ were annealed, then
amplified by using forward primer 5’-ACGTTCTA GACAACTTT
GTATACAAAAG-3’ and reverse primer 5’-
CATCGGATCCATAGTGACTGGATATG-3’. The resulting
fragments were inserted into XbaI/PvuII sites of pENTR-
Promoterless, in which the attL2 sequence has been removed.
The BGH polyA, isolated from pcDNA 3.1, was inserted into
XbaI/XhoI sites of pL1R5. The EF1α promoter was amplified
Table 1. TALEN Entry plasmid sets.
Entry Plasmidsa Applications
pENTR-EF1α-TALEN-NN-
T2A-EGFP
1. The TALEN Entry plasmid pairs can be used
for
pENTR-EF1α-TALEN-NI-T2A-
EGFP TALEN functional tests directly.
pENTR-EF1α-TALEN-NG-
T2A-EGFP 2. The TALEN Entry plasmids contain EGFP or
pENTR-EF1α-TALEN-HD-
T2A-EGFP mCherry reporter which can be used to monitor
 transfection efficiency and cell sorting. Bothreporters
pENTR-EF1α-TALEN-NN-
T2A-mCherry
can be removed from vectors through AscI
digestion.
pENTR-EF1α-TALEN-NI-T2A-
mCherry 3. T7 RNA polymerase promoter in these vectors
pENTR-EF1α-TALEN-NG-
T2A-mCherry enables in vitro transcription to produce mRNAs.
pENTR-EF1α-TALEN-HD-
T2A-mCherry
4. Through LR recombination, the TALEN
expression units can be transferred to pAd/PL-
DEST to generate TALEN adenoviruses.
aAbbreviations: EF1α, elongation factor 1α promoter; T2A,Thosea asigna virus 2A
peptide
doi: 10.1371/journal.pone.0080281.t001
from pEF-ENTR A using forward primer 5’ ATAAAGCTTGGG
AAAGTGATGTCGTGT-3’ and reverse primer 5’-
GCTAGCGCTAGCCGACACCTGAAATGGAAGAAA-3’. The
chicken β-actin (CAG) promoter was amplified from pCAG-
ERT2-CRE-ERT2 (Addgene #13777 ) using forward primer 5’-
ATTGATTATTGACTAGTTATTAATAG-3’ and reverse primer
5’-GCTAGCGCTTCTTTGCC AAAATGATGAGAC-3’. Each
promoter fragment was digested with HindIII/NheI and ligated
with EGFP-T2A and mCherry-T2A fragments isolated from
pEGFP-T2A-C1 and pmCherry-T2A-C1 via NheI/KpnI
digestion. The TALEN fragments were amplified from
pTALEN_V2 TALEN plasmids using forward primer 5’-
GCTAATCGATCTAGATTATGAGCGGAAATTGATCTCGCCA
TTG-3’
and reverse primer 5’-
GGTACCGGTACCATGGACTATAAGGACCACGAC-3’ and
digested with KpnI. Then promoters, reporters and TALEN
fragments were inserted into XhoI (blunted)/HindIII sites of
pL1R5-BGHpA or pL5L2 (Table 2 ).
Destination Plasmids
Adenoviral destination vector pAd/PL-DEST was from Life
Technologies (K4940-00). To make PiggyBac destination
vectors, we replaced the sequence between the SpeI and HpaI
sites of pPB-CuO-MCS-IRES-GFP-EF1-CymR-Puro (System
Biosciences, PBQM530A-1) with the sequence between the
NheI and HpaI sites of pEGFP-N1. The EGFP sequence was
then removed by digestion with BglII/NotI and replaced with a
multiple cloning sites sequence by annealed oligos 5’-
GATCCTTAATTAAGACTAGTCGAATT
CTGCAGTCGAGGTACCCGGGATCCTCTAGATGC-3’ and 5’-
GGCCGCTCTAGAGGATCCCGGGTACCTCGACTGCAGAAT
TCGACTAGTCTTAATTAAG-3’. Next, the fragment containing
attRI, chloramphenicol resistant gene, ccdB gene and attLR2
from pWS-TK6 (Addgene #20350 ) was amplified using forward
primer 5’-GATCTCTAG ACTCGATTTGTT AGCAGCCTCG-3’
and reverse primer 5’-
CGCATTAATTAATCGATGCGATCGCTAGC-3’ and then
inserted into PacI/XbaI sites of the PiggyBac plasmid to
generate pPB-DEST. To gain the puromycin selection marker,
the fragment containing Pgk-Puro was isolated from pLenti-
DEST-Pgk-Puro (Addgene #19068) by SalI/XbaI double
digestion and inserted into SalI/XbaI sites of pPB-DEST. The
new plasmid was named pPB-DEST-Puro.
Assembly of TAL effector RVDs into TALEN expression
Entry vectors
We designed TALENs targeted to mouse Ddx3 gene family
members, Ddx3x, Ddx3y, and D1Pas1. Ddx3x and Ddx3y are
located on the X and Y chromosomes, respectively. D1Pas1 is
an intronless retrotransposed copy of the Ddx3x gene and is
located on chromosome 1. We designed TALEN pairs to target
sequences such as the translation start site or intron/exon
junctions that are most likely to disrupt gene expression. In
addition, we targeted non-coding sequences, which are distinct
among family members. For Ddx3x, the left TALEN target
sequences are in the 5’ untranslationed region (5’UTR) of exon
1, and the right TALEN targets 5’UTR close to the coding
Assembly of Customized TALENs
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sequence. For Ddx3y, the left TALEN target sequences are in
intron 4, the right TALEN target sequences are in exon 5, and
the intervening sequence consists of part of intron 4 and exon
5. For the intronless D1Pas1, the TALEN targets were chosen
from the sequences corresponding to exon 1 (left TALEN) and
exon 2 (right TALEN) of Ddx3x. This combination is unlikely to
mutate Ddx3x or Ddx3y due to the intervening intron sequence.
For a pair of TALENs, each TALEN targets 20 base pairs of
sequences starting from “T” with a space of ~14-20 bases in
between. The middle 18 bases of each target sequence (the
RVD sequence) was divided into three hexamers that were
ligated into pTemp-S [15] . The RVDs were assembled into
TALEN Entry basic vectors through two continuous golden gate
ligation [49]. The detailed protocol is in Supplementary
Methods (Protocol S1 A). Half (~7 µl) of each final ligation
products were used to transform chemical competent DH 5α
cells. Six colonies were inoculated from each ligation. Plasmid
DNAs were extracted and screened by SalI digestion, then
Table 2. Library of TALEN Entry plasmids for 2-in-1
recombination.
Entry Plasmidsa Applications
pL1R5-BGHpA-empty 1. The TALEN Entry plasmid pairs canbe used for
pL1R5-CAG-EGFP-T2A-TALEN-NN-
BGHpA TALEN functional tests.
pL1R5-CAG-EGFP-T2A-TALEN-NI-
BGHpA
2. The TALEN Entry plasmids contain
EGFP or
pL1R5-CAG-EGFP-T2A-TALEN-NG-
BGHpA
mCherry reporters, which can be used
for
pL1R5-CAG-EGFP-T2A-TALEN-HD-
BGHpA
monitoring transfection efficiency and
cell sorting.
 3. Through LR recombination, theTALEN pairs can
pL5L2-empty be transferred to pPB-DEST or pPB-Puro-DEST or
pL5L2-EF1α-mCherry-T2A-TALEN-NN other destination vectors.
pL5L2-EF1α-mCherry-T2A-TALEN-NI 4. TALENs in pL1R5-BGHpA vectorstogether with
pL5L2-EF1α-mCherry-T2A-TALEN-NG pL5L2 empty vector can berecombined into
pL5L2-EF1α-mCherry-T2A-TALEN-HD pAd/PL-DEST to produceadenoviruses with CAG
 EGFP. Alternatively the reverseinsertion of
pL5L2-CAG-mCherry-T2A-TALEN-NN TALENs in pL5L2 vectors togetherwith pL1R5 -
pL5L2-CAG-mCherry-T2A-TALEN-NI BGHpA empty vector can berecombined into
pL5L2-CAG-mCherry-T2A-TALEN-NG pAd/PL-DEST to produceadenoviruses with EF1α
pL5L2-CAG-mCherry-T2A-TALEN-HD mCherry or CAG-mCherry.
aAbbreviations: L1 and L2, attL1and attL2 sites; R5 and L5, attR5 and attL5. CAG,
chicken β-actin promoter; T2A,Thosea asigna virus 2A peptide; BGHpA, bovine
growth hormone polyadenylation sequence; EF1α, elongation factor 1α promoter.
doi: 10.1371/journal.pone.0080281.t002
sequencing using primer TALE-Seq-F1, TALE-Seq-F2 and
TALE-Seq-R1 [15].
Transfer of assembled TALENs to the Destination
Vectors
To transfer the assembled TALENs into adenoviral
destination vectors, 150 ng of TALEN Entry vector and 150 ng
destination vector pAd/PL-DES), 2 µl Gateway® LR Clonase® II
Enzyme Mix (Life Technologies, 11791-020) and TE buffer (pH
8.0) were added up to 10 µl. After incubation at room
temperature for 2 hours, 4 µl of the product were directly added
into 50 µl DH5α competent cells for transformation.
For the “2 in 1” system, two TALEN Entry vectors (150 ng
each), the destination vector pPB-DEST or pPB- DEST-Puro
(150 ng), 2 µl Gateway® LR Clonase® II Plus Enzyme Mix (Life
Technologies, 12538-120) and TE buffer (pH 8.0) were added
up to 10 µl . After incubation at room temperature for 4 hours to
overnight, 4 µl of the product were directly added into 50 µl
DH5α competent cells for transformation. The restriction
digestion maps of all plasmids are presented in Protocol S1 B.
Production of Adenoviral vectors
Adenoviral vectors were produced in 293A cells according to
the instructions of ViraPowerTM Adenoviral Expression System
(Life Technologies, K4940-00). To determine the titers, the
viruses were serially diluted and added to 12-well plates pre-
seeded with HEK 293 cells. Seventy hours after transduction,
EGFP or mCherry expressing cells or colonies of cells were
counted to calculate plaque-forming units or transducing units.
TALEN plasmid transfection and viral vector
transduction
A Neuroblast cell line Neuro-2a (ATCC® CCL-131™) was
used for validation of TALEN function. The day before
transfection, 2-3x105 cells were seeded per well in a 24-well
plate. TALEN entry vector pairs (0.8 µg for each TALEN) or 1
ug for “2 in 1” vectors, were transfected into cells twice on two
consecutive days using Lipofectamine 2000 (Life
Technologies). The cells were collected 72 hours after the first
transfection and genomic DNA was extracted for further
analysis. For TALENs targeting Ddx3y gene (on Y
chromosome), primary fibroblasts derived from C57BL/6 male
mouse tail tips were used. All animal procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Pittsburgh, which is the IACUC of
record for Magee-Womens Research Institute (Assurance
number A3187-01), in accordance with the National Institutes
of Health Guidelines for the Care and Use of Laboratory
Animals. Mouse G4 embryonic stem cells and rat C6 glial
tumor cells (ATCC®-CCL-107™) were cultured with standard
protocols. Different cell lines were transduced with adenoviral
vectors using a multiplicity of infection (MOI) of 2-5.
Surveyor® mutation analysis and sequencing
Genomic DNA in plasmid transfected or virus transduced
cells was extracted and the genomic regions encompassing the
TALEN target sites in mouse Ddx3x, Ddx3y and D1Pas1 were
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amplified by PCR. The primers for amplification of Ddx3x were:
forward 5’-aagatt aggggaccggtgg- 3’, reverse 5’-
gacgggaaggaaaaagca- 3’; for Ddx3y: forward 5’-
gcccagcagtttgagctatt-3’, reverse 5’-gccatccttctgaccctgta-3’; and
for D1Pas1: forward 5’-gccatagcgttagcttggag-3’, reverse 5’-
catcctcgtctgctttgtca-3’. Genomic mutation assay was performed
according to SURVEYOR Mutation Detection Kit
(Transgenomic, 706020). Each experiment was replicated a
minimum of three times to establish the reproducibility of the
method. The PCR products with mutations were subcloned into
Zero Blunt PCR kit (Life Technologies, K2700-20) and
sequenced.
Results
TAL effector RVD plasmid array
To generate TALEN constructs targeted to genes in
mammalian cells, we adopted the TALEN toolbox from Zhang’s
group [15] with modifications described here. The assembly of
TALENs by PCR in the original strategy is straightforward, but
we frequently observed mutations or deletions that had been
introduced into TALENs, probably because tandem repeats of
the RVD sequences caused PCR errors. Therefore, we cloned
the TAL effector RVD in into pGEM-T vector to generate a RVD
array of forty plasmids for hexamer construction, and one
intermediate plasmid, pTemp-S. For TALEN assembly, while
position 2 to 5 of all hexamers share the same plasmids
encoding RVDs, NI (A), HD (C), NG (T), or NN (G)
respectively, different plasmids should be picked for the first
and last RVDs for different hexamers (Figure S1, Top ) to
facilitate ligation of RVD sequences to generate each hexamer.
The same intermediate plasmid pTemp-S is used for all
hexamer assembly. Generally, it is not necessary to transform
hexamer ligation products and screen the plasmids. However,
this is an option if the TALEN assembly by one-step
transformation fails (Figure S1, Bottom).
TALEN Entry vectors
The Gateway® technology (Life technologies), which is based
on the bacteriophage lambda site-specific recombination
system, is very efficient and specific for molecular cloning. In
this system, the sequences in the first plasmid (Entry vectors)
can be transferred to the second plasmid (Destination vector)
through attL/attR (LR) recombination [50,51], which is suitable
for choosing different TALEN delivery systems in the future.
We generated two sets of four TALEN Entry vectors
containing either EGFP or mCherry reporters, which are driven
by human EF1α promoter (Table 1). T7 RNA polymerase
promoter following EF1α promoter in these vectors can be
used for in vitro transcription to produce mRNAs.
We then used the new TALE RVD plasmid array and TALEN
Entry vectors to construct TALEN pairs to target mouse Ddx3
gene family members (Ddx3x, Ddx3y and D1Pas1). Each
TALEN binding sequence and RVDs are shown on Figure S2.
Using a two continuous golden gate ligation approach (Figure
1A, Protocol S1), we routinely obtained 4 to 6 out of 6 randomly
picked colonies with the correct sequences. Sequence
analyses did not reveal any mutations if the plasmid had the
correct restriction enzyme patterns. Except of those RVDs
which were synthesized chemically and ligated into TALEN
expression vectors [17,19,34], the comparison of our strategy
to others is provided in Table S1. We transfected TALEN Entry
plasmids targeted to Ddx3x and D1Pas1 into mouse Neuro 2a
cells. The transfection efficiency and TALEN expression were
easily monitored via expression of fluorescent reporter genes,
which were encoded from the same transcript as the TALENs
with intervening 2A sequences (Figure 1B-D). We favored this
approach over the approach of co-transfecting with a separate
reporter plasmid [26,29]. Furthermore, if the donor DNAs
containing either green or red fluorescent reporter are used for
homologous recombination, EGFP or mCherry in these
customized TALEN vectors can be simply removed by AscI
digestion and re-ligation. Surveyor® mutation analysis was
performed to validate the activity of each TALEN pair. As
shown in Figure 1E and F, any single TALEN (left or right)
vector targeting Ddx3x or D1Pas1 did not introduced mutations
around the target sequences. However, Co-transfection of
TALEN pairs resulted in mutagenesis that was revealed by
Surveyor mutation analysis.
Transfer of customized TALENs to adenoviral vector
Transfer of TALENs to non-integrating adenoviral vectors
would theoretically significantly enhance the efficiency of
TALEN delivery and broaden the potential applications of
TALEN technology. Therefore, we recombined TALEN pairs,
which targeted either Ddx3x or Ddx3y respectively, from their
Entry vectors into adenoviral destination vectors pAD/PL-DEST
(Figure 2A). The TALEN Entry vectors can be easily
transferred to adenoviral vectors by Gateway® LR
recombination.
We then generated TALEN adenoviruses for Ddx3x and
Ddx3y and tested them in either Neuro-2a cells or mouse
fibroblasts. Based on reporter gene expression shown in Figure
2B-D, the efficiency of Ddx3x TALEN adenovirus transduction
into Neuro-2a cells was qualitatively greater than that of
sequential (2x) TALEN plasmid transfections (Compare Figure
1B-D and Figure 2B-D). Surveyor® mutation analysis
demonstrated that adenovirus transduction with single TALENs
did not cause mutations at their target region, while adenovirus
transduction with TALEN pairs did (Figure 2H). The ratio of cut
to non-cut DNA from adenovirus-TALEN transduced samples
was approximately 50% (Figure 2H). Thus, higher efficiency of
adenoviral vector transduction resulted in higher genomic
mutagenesis (compare Figure 2H and Figure 1E). Similar
results were obtained for Ddx3y TALEN adenovirus pairs,
which were tested in mouse male fibroblasts (Figure 2F and I).
To show the tropism of virus and ubiquity of human EF1α
promoter, the adenoviruses were also transduced into mouse
G4 ES cells and rat C6 glioma cells (Figure 2E and G). During
the preparation of this manuscript, we note that Holkers and
coworkers used a different plasmid system to introduce TALEN
sequences in adenoviral vectors [52]. However, their cloning
strategy required several extra steps (see Discussion).
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Sequence analysis of Ddx3 genes after treatment with
plasmid or adenoviral TALENs
We cloned the PCR products amplified at the target regions
of Ddx3x and D1Pas1 from Neuro-2a cells which were
transfected with TALEN plasmid pairs (Figure 3A), and Ddx3y
from male mouse fibroblasts transduced with adenoviral
TALEN pairs (Figure 3B). We confirmed that the cells treated
with customized TALENs generated mutations around their
target sequences (Figure 3). The largest deletion detected in
Ddx3y was 193 bp (not shown).
Assembly of customized TALEN pair into one vector-“2
in 1”.  Because of the feature of FokI, TALENs must work as a
pair. We believe it should be beneficial for plasmid transfection
and DNA injection to engineer a customized TALEN pair into
one plasmid. We thought it may be feasible to clone both left
and right TALENs into one destination vector via the Multisite
Gateway® Pro system [53] (Life technologies). To enable this
Figure 1.  Assembly of RVDs into TALEN Entry plasmids and validation of TALEN function.  A. Repeat variable di-residues
(RVDs, see Figure S1) are assembled by golden gate ligation into pTemp-S intermediate plasmids (pHex1-3), which are
subsequently combined by golden gate ligation into the pENTR-TALEN entry vectors. No PCR amplification is required. TALEN
entry vectors contain mCherry or EGFP reporter genes. B-D. Example of transfection of Ddx3x TALEN Entry plasmids into mouse
Neuro-2a cells. B1-B2, Ddx3x left TALEN (with EGFP reporter); C1-C2; Ddx3x right TALEN (with mCherry reporter); D1-D2, Ddx3x
TALEN pair. B1, C1, D1, Phase contrast; B2, C2, D2, epifluorescence. E. Surveyor mutation analysis of Ddx3x gene after
transfection of Ddx3x TALENs vectors into Neuro-2a cells. F. Surveyor® mutation analysis of D1Pas1 gene after transfection of
D1Pas1 TALENs vectors into Neuro-2a cells. RVD, repeat variable di-residues. EF, human EF1α promoter. CmR, Chloramphenicol
resistance gene. ccdB, a lethal gene targeting DNA gyrase. FoKI, FoKI C-terminal domain. 2A, Thosea asigna virus 2A peptide.
Spec+, Spectinomycin resistance gene.
doi: 10.1371/journal.pone.0080281.g001
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approach, different att sites must be chosen for recombination
of two or more fragments into the Entry vectors.
We generated 12 TALEN Entry constructs. Four vectors,
which have attL1 and attR5 flanking sequences and EGFP
reporter for one side TALEN (e.g.,left TALEN) assembly, and
the other eight vectors, which hold attL5 and attL2 flanking
sequences and mCherry reporter for the other side TALEN
(e.g., right TALEN) assembly (Table 2). The assembly of RVDs
into these Entry plasmids followed the same procedure
described above. We also constructed two PiggyBac
Figure 2.  Transfer of TALEN sequences into adenoviral vectors and validation of TALEN function.  A. The left and right
TALEN sequences described in Figure 1 were transferred into an adenoviral destination vector, pAd/PL-DEST, by Gateway® LR
recombination. B-D, Example of transduction of Ddx3x TALEN adenoviruses into mouse Neuro-2A cells. B1-B2, left Ddx3x
adenoviral-TALEN. C1-C2, right Ddx3x adenoviral-TALEN. D1-D2, Ddx3x adenoviral TALEN pair. E1-E2, Transduction of Ddx3y
adenoviral-TALEN pair (both linked to mCherry) into male mouse fibroblasts. F1-F2, Transduction of Ddx3x adenoviral TALEN pair
into mouse ES cells; left TALEN linked to EGFP and right TALEN linked to mCherry. G1-G2, Transduction of Ddx3y adenoviral-
TALEN pair (both linked to mCherry) into rat C6 cells. H. Surveyor® mutation analysis of Ddx3x gene after transduction with Ddx3x
adenoviral-TALENs into Neuro-2a cells. I. Surveyor® mutation analysis of Ddx3y gene after transduction of Ddx3y adenoviral-
TALENs into male mouse fibroblasts.
doi: 10.1371/journal.pone.0080281.g002
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Figure 3.  TALEN-induced mutations in mouse Ddx3 subfamily genes.  A. DNA sequence analysis of Ddx3x and D1Pas1
genes in Neuro 2A cells after transfection with plasmid TALENpairs. B. DNA sequence analysis of Ddx3y gene in male mouse
fibroblasts after transduction with adenoviral-TALEN pairs. TALEN binding sequences are underlined. Stars indicate the identical
sequences. Dashes indicate missing nucleotides compared to the wild type (WT) sequences. Exon 5 sequences of Ddx3y are in
bold.
doi: 10.1371/journal.pone.0080281.g003
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transposon-based destination vectors, pPB-DEST and pPB-
DEST-Puro (Figure 4A). This system can be readily modified
for other destination vector systems.
As a proof of concept, we generated a pair of Entry TALEN
vectors targeting exon 1 of the Ddx3x gene using same RVDs
described above. We then recombined into the pPB-DEST and
pPB-DEST- Puro destination vectors. The two fragment
recombination was effective, despite the fact that thirty-six
RVDs (eighteen RVDs for each side TALEN) were present in
the sequences. It should be pointed out that it is impossible to
sequence the RVDs in the final vectors. Nonetheless, we
transfected each TALEN Entry plasmid (Figure 4B and C) and
Figure 4.  Combination of a TALEN pair into one plasmid vector.  A. Left and right TALENs were ligated into different Entry
plasmids to produce the “2 in 1” TALEN system. The left TALEN Entry vector contained attL1 and attR5 flanking sequences and the
EGFP reporter. The right TALEN Entry vector contained attL5 and attL2 flanking sequences and the mCherry reporter. The left and
right TALEN Entry vectors were then combined into the pPB-DEST destination vector by Gateway® LR recombination. In some
cases Pgk-Puro was added to the destination vector to facilitate selection. B-D Example of transfection of Ddx3x TALEN plasmids
into mouse Neuro-2a cells. B1 and B2: left Ddx3x TALEN Entry plasmid. C1 and C2, right Ddx3x TALEN Entry plasmid. D1 to D4, “2
in 1” Ddx3x TALEN plasmid. B1, C1, D1, phase contrast; B2, C2, D2, D3, D4, epifluorescence. E. Surveyor mutation analysis of the
Ddx3x gene after transfection of the individual left (lane 1) or right (lane 2) Ddx3x TALEN Entry plasmids or the “2 in 1“ Ddx3x
TALEN plasmid (lane 3) into Neuro-2a cells.
doi: 10.1371/journal.pone.0080281.g004
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the TALEN “2 in 1” plasmid (Figure 4D) into Neuro-2a cells.
Surveyor® mutation analysis demonstrated that the TALEN pair
assembled in one plasmid (“2 in 1”) was capable of introducing
mutations in genome (Figure 4E).
Discussion
Several groups have reported different systems for
customized TALEN assembly [15–17,19,20,32,36,38,54–56].
Most reports have utilized plasmid-based TALEN expression
systems and tested function by transfection of TALEN pairs
into cell lines which were easily transfected by lipofection
[15,17–19,29,57,58], electroporation [16,31,59,60] or direct
injection of DNA or mRNAs [21,32,59–61]. However, many cell
lines and primary cells are difficult to transfect efficiently. In
many cases, this obstacle can be circumvented using viral
vectors. These challenges prompted us to devise methods to
facilitate accurate TALEN assembly (RVD plasmid array and
Entry vector) and design efficient delivery systems (adenovirus
and 2 in 1 plasmids).
Our TALEN assembly approach exploits the features of the
methodology originally described by Sanjana and colleagues
[15]. However, we assembled TALENs using a sequence
validated array of RVD plasmid encoding repeat monomers,
which eliminated possible errors introduced by PCR. We used
these basic materials to assemble TALENs targeting three
genes of Ddx3 gene family, which are located on chromosome
1 (D1Pas1), the X chromosome (Ddx3x) and the Y
chromosome (Ddx3y) and did not observe any mutations in our
assembled TALEN constructs. The system described here
saves the time and labor of amplification and purification of
PCR products, relative to PCR only [15,20,24,54] or PCR-
plasmid mixed assembly [16] approaches. In addition, our
approach eliminated an extra step of transformation compared
to other plasmid-based assembly approaches [18,29,38,62].
The TALEN Entry vectors generated in this study (Table 1)
contain fluorescent reporters (EGFP or mCherry), which help to
evaluate the transfection efficiency and can facilitate tracking
and sorting of cells containing the TALEN moiety. Furthermore,
the new TALEN Entry vector sets are in a Gateway® Entry
vector-based system, which can be easily transferred to other
delivery system, such as viral or transposon vectors through in
vitro LR recombination. Indeed, we successfully transferred
TALEN-reporter expression units into adenoviral plasmids
without losing any TALEN expression unit sequences.
Adenoviral vectors efficiently transduce dividing or non-dividing
mammalian cells and can be produced at high titers. We
demonstrated in the current study that adenoviral TALENs can
effectively modify target gene sequences. During preparation of
this manuscript, Holkers and co-workers reported similar
success using adenoviruses to introduce TALEN sequences
into HeLa cells with a different strategy [52]. To generate
adenoviral TALEN plasmid in that study, the authors first
assembled the TALEN sequence into an expression vector,
then isolated the TALEN sequences and inserted them into a
shuttle vector, followed by HR in Escherichia coli
BJ5183pAdEasy-1 to get adenoviral TALEN vectors [52]. In the
current study, we report a relatively simple strategy in which
adenoviral TALEN vectors are assembled directly from TALEN
Entry plasmids in the test tube via LR recombination. The fact
that adenoviral vectors rarely integrate in the genome may be
advantageous in some experimental circumstances. For some
studies, the adenovirus-TALEN approach described here may
provide a viable alternative to lentiviral vector-based small RNA
knockdown systems that are currently widely used.
We also built a set of TALEN Entry plasmids with different att
flanking sequences, which can be used to join TALEN pairs
into PiggyBac transposon-based destination vectors (2 in 1
system). The targeting efficiency of one plasmid transfection
should theoretically be higher than that of two plasmids. The
individual Entry TALEN vectors for the “2 in 1” system can also
be recombined to pAd/PL-DEST adenoviral vectors. However,
because of adenovirus genome size limitations, the new
generation of gutless adenoviral vectors [63] may be required
to assemble the “2 in 1” TALEN system in adenoviruses.
Cloning of TALEN expression units into PiggyBac vectors could
also increase transfection efficiency if co-transfected with
transposase. This system may not be limited for TALEN
assembly. For example, by replacement of the FokI C-terminal
domain in TALEN vectors with transcriptional activator or
repressor domains, and generation of new multisite Gateway®
Entry plasmids, we could regulate 2 to 4 genes by using a
single plasmid because the PiggyBac transposon system has
been shown to deliver cargo sizes larger than 200 kb [64–67].
Furthermore, integrated TALE PiggyBac transposons can be
removed from the genome by transient expression of
transposase without leaving a “footprint” [68,69].
Future advances in the TALEN field will improve specificity,
which is important for cell therapy. This could be done, for
example, by adding new Asn-His (NH) or Asn-Lys (NK) RVDs,
which have high biological activity and specificity for G [43,57]
into the array or by use of mutated FokI C-terminal domain DD
and RR in TALEN Entry vectors to reduce off-target nuclease
activity [68]. In this work, we developed a robust and accurate
TALEN assembly system and “user friendly” TALEN Entry
vectors that can be modified by basic molecular biology
methods to take advantage of new developments in the TALEN
field.
Supporting Information
Figure S1.  Repeat variable di-residue (RVD) plasmid
library and hexamer assembly. Upper: RVDs library plasmids
for TALEN assembly. Lower: example of assembly of 3
hexamers for the left TALEN of exon 1 of Ddx3x.
(PDF)
Figure S2.  TALENs’ target sequences of Ddx3x, Ddx3y
and D1Pas1. The TALEN pair for Ddx3x targets the 5’
untranslated region. The TALEN pair for Ddx3y targets intron 4
(left TALEN, red) and exon 5 (Right TALEN, blue). The TALEN
pair of the D1Pas1 (retrotransposed autosomal copy of Ddx3x)
targets sequences corresponding to exon 1 (for left TALEN,
red) and exon 2 (for right TALEN, blue) of Ddx3x. The left and
right TALEN target sequences for each gene are indicated with
bold underlines. The assembled RVDs (with encoded
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